retinyl valerate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: retinyl valerate
• 英文别名: retinol valerate；[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] pentanoate
• 化学式: C₂₅H₃₈O₂
• 分子量: 370.576
• InChiKey: NZFANTPWRRCKOJ-DWACINBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  戊酸酐 、 维生素A 在 1-pentyl-3-methylimidazolium nitrate 作用下， 反应 3.0h， 生成 retinyl valerate
  参考文献：
  名称：

  Using imidazolium-based ionic liquids as dual solvent-catalysts for sustainable synthesis of vitamin esters: inspiration from bio- and organo-catalysis

  摘要：

  开发了一种使用咪唑基离子液体作为双溶剂催化剂的高效和可持续方法，用于合成维生素E酯。

  DOI：

  10.1039/c5gc02557e

文献信息

• Chroman derivatives as lipoxygenase inhibitors
  申请人：Zhang Wei

  公开号：US20060193797A1

  公开（公告）日：2006-08-31

  The present invention is concerned with certain novel derivatives of Formula I: wherein X and R 1 to R 10 are as described in the specification, and where either R 5 is OH, —NR d OR a or —NR d —NR b R c , or R 7 is —NR d OR a or —NR d —NR b R c , or C═R 7 R 8 is C═NOR a or C═N—NR b R c , which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of skin care and/or pharmaceutical compositions for the treatment of lipoxygenase mediated disorders.

  本发明涉及Formula I的某些新颖衍生物：其中X和R1至R10如规范中所述，其中R5为OH，—NRdORa或—NRd—NRbRc之一，或R7为—NRdORa或—NRd—NRbRc之一，或C═R7R8为C═NORa或C═N—NRbRc，这些可能在制造用于治疗通过脂氧合酶介导的疾病的药物组合物中有用。它们还可能在制造用于治疗脂氧合酶介导疾病的皮肤护理和/或药用组合物中有用。
• [EN] ISOMERIZATION OF POLYUNSATURATED NON-AROMATIC COMPOUNDS<br/>[FR] ISOMÉRISATION DE COMPOSÉS NON AROMATIQUES POLYINSATURÉS
  申请人：BASF SE

  公开号：WO2020245030A1

  公开（公告）日：2020-12-10

  The invention relates to an improved process for isomerizing polyunsaturated non-aromatic compounds including acyclic conjugated polyenes and alicyclic conjugated polyenes. In particular it relates to an improved and safe process for forming a 11-E retinoid compounds in high yield by expending as few energy as possible and with avoiding at most possible side products or product mixtures. This is achieved by feeding at least one of retinoid compounds of formula 2 to 5, or at least one of retinoid compounds of formula 2 to 5 and retinoid compound of formula 1, an organic solvent and a photosensitizer into a reaction device and irradiating the thus obtained reaction mixture with visible monochromatic light, at least 90 % of the power of said monochromatic light and at most 100 % of said power being emitted in the range from 460 nm to 580 nm.

  本发明涉及一种改进的过程，用于异构化多不饱和非芳香化合物，包括无环共轭多烯和脂环共轭多烯。特别是，它涉及一种改进和安全的过程，通过尽可能少地消耗能量并尽可能避免副产物或产物混合物的形成，以高产率形成11-E视黄醇类化合物。这通过将公式2至5的至少一种视黄醇化合物或公式2至5的至少一种视黄醇化合物和公式1的视黄醇化合物、有机溶剂和光敏剂进入反应装置，并用可见单色光照射所得到的反应混合物来实现，所述单色光的至少90％的功率和最多100％的功率在460nm至580nm范围内发射。
• Management of ophthalmologic disorders, including macular degeneration
  申请人：Rando R. Robert

  公开号：US20060069078A1

  公开（公告）日：2006-03-30

  A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

  一种药物可以用于制备治疗或预防眼科疾病的药物，其中该药物抑制、拮抗或短路视觉循环，该视觉循环发生在杆状感光细胞的盘外步骤。
• Management of Ophthalmologic Disorders, Including Macular Degeneration
  申请人：Rando Robert R.

  公开号：US20080176952A1

  公开（公告）日：2008-07-24

  A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

  一种药物可用于制备用于治疗或预防眼科疾病的药物，其中该药物抑制、拮抗或短路视觉周期，在视网膜杆细胞盘外发生的视觉周期步骤中。
• TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST
  申请人：Nitto Denko Corporation

  公开号：US20130210744A1

  公开（公告）日：2013-08-15

  Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer.

  本发明涉及一种新的治疗剂和癌症的新治疗方法。具体涉及的是：一种针对癌细胞和癌相关成纤维细胞中所选细胞的靶向剂，包括维甲酸和/或其衍生物；一种用于该细胞的物质传递载体，包括靶向剂；一种利用靶向剂或载体的抗癌组合物；一种抗癌相关成纤维细胞组合物；以及一种癌症治疗方法。